Table 1.
Internalizing symptoms, baseline to 24 months.
| Unadjusted Means | Within-Group Slopes 1 | Btw Grp Diff | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Outcome Variables | CATCH-IT (N = 193) | HE (N = 176) | CATCH-IT | HE | ||||||||||
| N | Mean | SD | N | Mean | SD | Time Variable | b | SE | p | b | SE | p | p | |
| SCARED 2 total score (0–82) | Months | −0.13 | (0.06) | 0.04 | −0.11 | (0.06) | 0.07 | 0.79 | ||||||
| Baseline | 171 | 25.5 | (12.7) | 141 | 25.2 | (11.9) | ||||||||
| 2 months | 94 | 26.2 | (13.1) | 90 | 25.7 | (14.3) | ||||||||
| 6 months | 74 | 25.1 | (15.0) | 92 | 24.0 | (13.9) | ||||||||
| 12 months | 83 | 22.4 | (13.0) | 73 | 23.2 | (13.6) | ||||||||
| 18 months | 64 | 25.6 | (13.3) | 81 | 23.2 | (13.4) | ||||||||
| 24 months | 39 | 19.6 | (12.2) | 54 | 20.9 | (13.7) | ||||||||
| CES-D10 (0–30) | Months | −0.06 | (0.02) | 0.01 | −0.04 | (0.02) | 0.10 | 0.44 | ||||||
| Baseline | 190 | 9.5 | (4.5) | 172 | 9.4 | (4.6) | Sqrt (months) | −0.31 | (0.11) | 0.004 | −0.27 | (0.10) | 0.009 | 0.80 |
| 2 months | 123 | 9.2 | (4.2) | 140 | 7.9 | (5.2) | ||||||||
| 6 months | 116 | 8.2 | (4.9) | 133 | 7.9 | (4.7) | ||||||||
| 12 months | 115 | 7.9 | (5.3) | 126 | 7.1 | (4.7) | ||||||||
| 18 months | 67 | 7.9 | (5.9) | 81 | 7.5 | (5.6) | ||||||||
| 24 months | 79 | 7.7 | (5.8) | 103 | 8.1 | (5.6) | ||||||||
1 From linear mixed effect growth models with random intercept and slope, adjusted for sex, ethnicity (Hispanic, non-Hispanic), race (white, non-white), baseline age, site, and baseline teen CES-D10. Within-group estimated slopes and p-values are from estimates of simple slopes. The p-value for the visit*time interaction is used to test for a significant difference between slopes. 2 Higher scores indicate greater anxiety.